CN102225127A - Traditional Chinese medicine composite for treating mastitis of dairy cattle - Google Patents
Traditional Chinese medicine composite for treating mastitis of dairy cattle Download PDFInfo
- Publication number
- CN102225127A CN102225127A CN2011101664167A CN201110166416A CN102225127A CN 102225127 A CN102225127 A CN 102225127A CN 2011101664167 A CN2011101664167 A CN 2011101664167A CN 201110166416 A CN201110166416 A CN 201110166416A CN 102225127 A CN102225127 A CN 102225127A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- mastitis
- herba
- medicine composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a traditional Chinese medicine composite for treating the mastitis of dairy cattle. The traditional Chinese medicine composite is characterized by comprising the following components in percentage by weight: 20-40% of dahurian patrinia herb, 20-40% of arrowshaped tinospora root, 10-20% of sedum lineare, 10-20% of pipewort, 10-20% of hematoxylon, 10-20% of cortex erythrinae, 5-10% of concha arcae, 5-10% of eupatorium, 5-10% of inula japonica thunb, 1-5% of tribulus terrestris and 1-5% of pericarpium arecae. The composite provided by the invention is added with conventional auxiliary materials to be prepared into powder, oral liquid, breast perfusion and injection which are acceptable in clinic through the conventional process in pharmacy.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, especially relate to a kind of Chinese medicine composition for the treatment of bovine mastitis.
Background technology
Bovine mastitis (bovine mastitis) is a kind of inflammatory variation of mammary gland with physics, chemistry, microorganism, is characterized in Ruzhong somatic cell, particularly leukocytosis, and mammary gland tissue generation pathological change.Be to influence the development of world dairy, a kind of common frdquently encountered disease that brings about great losses to Dairy Production.It is reported that the positive rate of mastitis in China cows can be up to 40%～80%.Join in a common effort meter according to U.S.'s milk, subclinical type bovine mastitis sickness rate is up to 50%, and total incidence can account for 70% of whole cows.The milch cow that suffers from mastitis, head all daily yielding reduces 1.17kg, directly cause milk modification and drug residue and can't eat, part Niu Wufa cures and be eliminated, treat mastitis expense costliness, the sick cattle additional effort power of nursing and increase etc., even more serious is that some mastitis has infectiousness, and the infection of several cattle often can cause spreading of whole cattle farm mastitis.This shows that production brings enormous economic loss to mastitis to dairy industry.Therefore, how effectively to prevent and treat various types of mastitis and become world subject.
Antibiotic remains the main means of control bovine mastitis at present, but people also recognize the problem that antibiotic can not fundamentally solve bovine mastitis of depending merely on.Antibiotic reaches valid density in the milk because whole body or breast innerlich anwenden all are difficult to make.Particularly microorganism such as staphylococcus aureus can colonize in the cell, or forms L-type bacterium behind antibiotic therapy, and they are not grown on standard medium, but can exist the chronic infection breast.This shows, long-term a large amount of generation of using antibiotic not only to cause Resistant strain, reduce therapeutic effect, antibiotic also makes the milch cow immunologic function be suppressed simultaneously, cause easily again and infect, the more important thing is, drug tolerant bacteria also can be given the people by milk-born infection, in addition, residual antibiotic also can bring out into body generation allergy in the milk.Along with the growing interest of people to food safety, antibiotic control bovine mastitis is faced with huge pressure.
Adopting Chinese medicine to treat bovine mastitis is a valid approach, and this is because the Chinese herbal treatment mastitis, not only has in the body, the good result of vitro inhibition, and can improve the immunologic function of subclinical mastitis milch cow, reaches treating both the principal and secondary aspects of a disease.Tcm therapy has advantages such as curative effect height, rehabilitation speed be fast to mastitis, and the medicine valency is cheap, and is simple to operate, do not have bad sequela.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition for the treatment of bovine mastitis, said composition contains the raw material of Chinese medicine of following weight ratio:
Herba Patriniae 20-40, Radix Tinosporae 20-40, Herba Sedi Linearis 10-20, Flos Eriocauli 10-20, Lignum Sappan 10-20, Cortex erythrinae 10-20, Concha Arcae 5-10, Herba Eupatorii 5-10, Flos Inulae 5-10, Fructus Tribuli 1-5, Pericarpium Arecae 1-5.
Most preferably, said composition contains the raw material of Chinese medicine of following weight ratio:
Herba Patriniae 35, Radix Tinosporae 35, Herba Sedi Linearis 15, Flos Eriocauli 15, Lignum Sappan 15, Cortex erythrinae 15, Concha Arcae 7, Herba Eupatorii 8, Flos Inulae 8, Fructus Tribuli 3, Pericarpium Arecae 3.
Chinese medicine composition of the present invention can be made various types of pharmaceutical preparatioies, for example powder, oral liquid, breast perfusion preparation, injection according to actual needs.In order to prepare these preparations, can add conventional pharmaceutic adjuvant as required in the present invention, for the selection of adjuvant, those skilled in the art can carry out according to the requirement of dosage form.
Concrete preparation technology is as follows for the present composition:
The compositions crude drug of getting it filled according to the pharmaceutics common process, adds conventional adjuvant, makes the acceptable powder of veterinary clinic, oral liquid, breast perfusate, injection.
The preferred breast perfusate of dosage form of the present invention.
What the present invention is directed to is the bovine mastitis disease, and Chinese veterinarian's theory is thought, that mastitis are promptly suckled is swollen, milk yellow, acute mastitis, is that expectorant, wet, gas, blood stagnation knot do not loose, and changes and is scorching.This disease and liver stomach two are through relevant, and because of feeding and management is not good at, the ground that lying on bed for a long time is damp and hot steams on the damp and hot poison, infringement mammary gland; Or because of excessiveness of stomach-heat, stagnation of QI due to depression of the liver, newborn network lose smooth consequently mammary gland coagulation of QI-blood, the stasis of blood is tied and living carbuncle.Determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs of the present invention, with heat-clearing and toxic substances removing, dredge the meridian passage is the rule of treatment, adopts monarch principle prescription, this compositions is treated at the different causes of disease of mastitis, many target spots, produces very strong synergism between each medicine, can improve tens of times of curative effects.
We are monarch drug with the Herba Patriniae of merit with heat-clearing and toxic substances removing, Radix Tinosporae.Herba Patriniae, hot, bitter, be slightly cold, return stomach, large intestine, Liver Channel, heat-clearing and toxic substances removing, eliminating carbuncle evacuation of pus are held concurrently with stasis-dispelling and pain-killing.Radix Tinosporae, hardship, cold, return lung, large intestine channel, heat-clearing and toxic substances removing, available treating acute and chronic tonsillitis, acute pharyngolaryngitis, stomatitis, parotitis, mastitis, appendicitis, carbuncle furuncle.Herba Sedi Linearis, Flos Eriocauli, Lignum Sappan, Cortex erythrinae, Concha Arcae are all ministerial drug.Wherein Herba Sedi Linearis is sweet, and is cold, returns lung, spleen channel, heat-clearing and toxic substances removing, and detumescence can be worked in coordination with the disease of monarch drug treatment acute mastitis redness.Flos Eriocauli, hot, sweet, flat, return liver, lung meridian, clearing away heat-fire, dispelling wind and heat pathogens can be worked in coordination with the dispel heat of liver, lung of monarch drug.Lignum Sappan, sweet, salty, little suffering, flat.GUIXIN, liver, spleen channel can promoting blood circulation to restore menstrual flow, again can stasis-dispelling and pain-killing, and the disease that the blood stasis that can control knot is do not diffusing can reach the effect of pain relieving, the disease that collaborative monarch drug elimination acute mastitis swells and ache simultaneously.Cortex erythrinae, bitter, hot, flat, go into liver, spleen channel, wind-damp dispelling, the meridian dredging, parasite killing, analgesic blood stasis dispelling, removing toxic substances and promoting granulation is controlled acute mastitis.Concha Arcae, salty, flat, go into lung, stomach, Liver Channel, but both blood stasis-eliminating and stagnation-dissipatings, again can eliminating phlegm and softening indurated mass, be suitable for the lump in the abdomen mass in the abdomen due to qi depression to blood stasis and the accumulation of phlegm.Herba Eupatorii, Flos Inulae are all adjuvant drug.Herba Eupatorii, hot, flat, return spleen, stomach, lung meridian, expelling summer-heat and damp is warded off dirty and middle resolving depression eliminating stagnation, kills diseases due to noxious agents produced by various parasites, can assist the merit of ministerial drug resolving depression eliminating stagnation.Flos Inulae, bitter, hot, salty, tepor is returned lung, stomach, large intestine channel, and hardship is let out suffering and is opened, and tepor master falls, can the expectorant of therapeutic method to keep the adverse QI flowing downwards row water, the gastric qi preventing or arresting vomiting can fall again, and can lead monarch drug, ministerial drug to enter focus, assist the effect of its performance heat-clearing and toxic substances removing.Fructus Tribuli, Pericarpium Arecae are all messenger drug.Fructus Tribuli, bitter, hot, flat, return Liver Channel, hardship is let out hot loosing, and property is flat cooler, specially goes into Liver Channel, and the breast side of body that can be used for depression of liver-QI does not relax, breast closes obstructed.Pericarpium Arecae, suffering, tepor is gone into spleen, stomach, large intestine channel.The circulation of qi promoting intestinal stasis relieving, damp eliminating.Both lead all medicines to go into breast focus place as messenger drug.
The specific embodiment
Embodiment 1
A kind of Chinese medicine composition for the treatment of bovine mastitis, it contains the raw material of Chinese medicine of following weight ratio: Herba Patriniae 35, Radix Tinosporae 35, Herba Sedi Linearis 15, Flos Eriocauli 15, Lignum Sappan 15, Cortex erythrinae 15, Concha Arcae 7, Herba Eupatorii 8, Flos Inulae 8, Fructus Tribuli 3, Pericarpium Arecae 3.Its preparation method is, according to the pharmaceutics common process, adds conventional adjuvant, makes breast perfusate (every 1ml is equivalent to crude drug in whole 2g) or oral liquid (every 1ml contains crude drug in whole 1g).
Embodiment 2
A kind of Chinese medicine composition for the treatment of bovine mastitis, it contains the raw material of Chinese medicine of following weight ratio: Herba Patriniae 20, Radix Tinosporae 20, Herba Sedi Linearis 10, Flos Eriocauli 10, Lignum Sappan 10, Cortex erythrinae 10, Concha Arcae 5, Herba Eupatorii 5, Flos Inulae 5, Fructus Tribuli 1, Pericarpium Arecae 1.Its preparation method is, according to the pharmaceutics common process, adds conventional adjuvant, makes breast perfusate (every 1ml is equivalent to crude drug in whole 2g) or injection (every 1ml is equivalent to crude drug in whole 2g).
Embodiment 3
A kind of Chinese medicine composition for the treatment of bovine mastitis, it contains the raw material of Chinese medicine of following weight ratio: Herba Patriniae 40, Radix Tinosporae 40, Herba Sedi Linearis 20, Flos Eriocauli 20, Lignum Sappan 20, Cortex erythrinae 20, Concha Arcae 10, Herba Eupatorii 10, Flos Inulae 10, Fructus Tribuli 5, Pericarpium Arecae 5.Its preparation method is, according to the pharmaceutics common process, adds conventional adjuvant, makes breast perfusate (every 1ml is equivalent to crude drug in whole 2g) or powder.
Embodiment 4
A kind of Chinese medicine composition for the treatment of bovine mastitis, it contains the raw material of Chinese medicine of following weight ratio: Herba Patriniae 30, Radix Tinosporae 30, Herba Sedi Linearis 13, Flos Eriocauli 13, Lignum Sappan 12, Cortex erythrinae 12, Concha Arcae 6, Herba Eupatorii 7, Flos Inulae 7, Fructus Tribuli 2, Pericarpium Arecae 4.Its preparation method is, according to the pharmaceutics common process, adds conventional adjuvant, makes breast perfusate (every 1ml is equivalent to crude drug in whole 2g) or oral liquid (every 1ml is equivalent to crude drug in whole 1g).
(1) to the extracorporeal bacteria inhibitor test of bovine mastitis The main pathogenic fungi
Adopt the dull and stereotyped diffusion method of agar gel, with from the sick Lac Bovis seu Bubali juice of suffering from bovine mastitis, extract three kinds of pathogen---staphylococcus aureus, streptococcus agalactiae, escherichia coli are that test sample carries out extracorporeal bacteria inhibitor test with the prepared infusion liquid of embodiment 1-4 respectively as test organisms.The result shows: 4 kinds of infusion liquid all have stronger antibacterial and bactericidal action to staphylococcus aureus, streptococcus agalactiae, escherichia coli.
(2) clinical treatment test
Bovine mastitis can be divided into recessive type mastitis and clinical type mastitis clinically, and this test will suffer from that cattle is divided into recessive type and clinical type carries out therapeutic test for two groups.
1 grouping of test milk cattle and test method
1.1 recessive type mastitis treatment group
Choose the milch cow of natural occurrence,, press following standard determination result with at first detecting with mastitis diagnostic reagent SMT: negative (-), mixture does not have precipitation, no change color; Suspicious (±) has the property a crossed finely ground particles to occur; Weak positive (+) has obvious sediment, but gel-free shape thing; Positive (++); Mixture coagulation jelly and assemble immediately after the jolting to the center, it is green that color is, and it is smooth to stop the jolting rear surface; Strong positive (+++), mixture coagulation agglutination immediately after the jolting, green, sticky, stop jolting after, central protrusion does not disappear.Select ++ above positive breast district filters out 120 of the positive milk cattles of recessive type mastitis as test breast district.Be divided into 6 groups, 1 group is, blank group, not administration; 2 groups of positive medicine matched groups give the treatment of ampicillin and streptomycin; The 3-6 group gives embodiment 1-4 prepared Chinese medicinal composition preparation.Test grouping and medication see Table 1.After the medication, tracing observation and inspection record are suffered from the cattle clinical symptoms and the mental status.
Table 1 recessive type mastitis treatment component group and medication
1.2 clinical type mastitis treatment group
There are pain reaction, milk-quality decline index to select 120 of clinical type mastitis disease cattle according to sick cow breast redness, heating, palpation.Be divided into 6 groups, 1 group is, blank group, not administration; 2 groups of positive medicine matched groups give the treatment of ampicillin and streptomycin; The 3-6 group gives embodiment 1-4 prepared Chinese medicinal composition preparation.Test grouping and medication see Table 2.After the medication, tracing observation and inspection record are suffered from the cattle clinical symptoms and the mental status.
The clinical type mastitis treatment of table 2 component group and medication
2 curative effect judging standards
2.1 recessive type mastitis treatment group
Cure: the treatment back is checked negative with the SMT method;
Effectively: the treatment back checks that with the SMT method positive reaction reduces more than 1 "+";
Invalid: treatment back checks with the SMT method, indifference before its positive reaction and the treatment, even increase the weight of or transfer clinical type mastitis to.
2.2 clinical type mastitis treatment group
Cure: clinical symptoms disappears, and milk character, color and milk yield are all recovered normally, and somatic number (SCC) is less than 500,000/mL in the LMT detection milk;
Effectively: clinical symptom relief, milk still have a small amount of grumeleuse, and milk yield is gone up, and dairy food quality rises, and LMT detects SCC more than 500,000/mL;
Invalid: the every index of clinical symptoms and milk does not all have being clearly better or increases the weight of, and LMT detects SCC more than 500,000/mL.
3 results
3.1 recessive type mastitis treatment group
Recessive type mastitis treatment group milch cow therapeutic outcome sees Table 3.
Table 3 recessive type mastitis treatment group milch cow therapeutic outcome
Can be drawn by table 3 result, Chinese medicine composition of the present invention is used for the treatment of recessive type bovine mastitis therapeutic effect and is better than western medicine group.
3.2 clinical type mastitis treatment group
Clinical type mastitis treatment group milch cow therapeutic outcome sees Table 4.
The clinical type mastitis treatment of table 4 group milch cow therapeutic outcome
Can be drawn by table 4 result, Chinese medicine composition of the present invention is used for the treatment of clinical type bovine mastitis therapeutic effect and is better than western medicine group.
Therefore, Chinese medicine composition of the present invention can be used for treating bovine mastitis, and determined curative effect, has no side effect at noresidue.
Claims (3)
1. Chinese medicine composition for the treatment of bovine mastitis, it is characterized in that said composition contains the raw material of Chinese medicine of following weight ratio: Herba Patriniae 20-40, Radix Tinosporae 20-40, Herba Sedi Linearis 10-20, Flos Eriocauli 10-20, Lignum Sappan 10-20, Cortex erythrinae 10-20, Concha Arcae 5-10, Herba Eupatorii 5-10, Flos Inulae 5-10, Fructus Tribuli 1-5, Pericarpium Arecae 1-5.
2. Chinese medicine composition as claimed in claim 1 is characterized in that the contained crude drug weight ratio of this Chinese medicine composition is as follows: Herba Patriniae 35, Radix Tinosporae 35, Herba Sedi Linearis 15, Flos Eriocauli 15, Lignum Sappan 15, Cortex erythrinae 15, Concha Arcae 7, Herba Eupatorii 8, Flos Inulae 8, Fructus Tribuli 3, Pericarpium Arecae 3.
3. as Chinese medicine composition as described in the claim 1,2, it is characterized in that this Chinese medicine composition makes powder, oral liquid, breast perfusate, injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101664167A CN102225127B (en) | 2011-06-21 | 2011-06-21 | Traditional Chinese medicine composite for treating mastitis of dairy cattle |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101664167A CN102225127B (en) | 2011-06-21 | 2011-06-21 | Traditional Chinese medicine composite for treating mastitis of dairy cattle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102225127A true CN102225127A (en) | 2011-10-26 |
| CN102225127B CN102225127B (en) | 2012-08-15 |
Family
ID=44806156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101664167A Active CN102225127B (en) | 2011-06-21 | 2011-06-21 | Traditional Chinese medicine composite for treating mastitis of dairy cattle |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102225127B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027699A (en) * | 2014-06-23 | 2014-09-10 | 烟台瑞智生物医药科技有限公司 | Traditional Chinese medicine (TCM) for treating distending pain of breasts during menstruation induced by symptom of deficiency of liver and kidney |
| EP3258948A4 (en) * | 2015-02-16 | 2018-09-12 | Zivo Bioscience, Inc. | Methods of modulating immune and inflammatory responses via administration of an algal biomass |
| US10166270B2 (en) | 2004-04-23 | 2019-01-01 | Zivo Bioscience, Inc. | Composition and method for affecting cytokines and NF-κB |
| US10232028B2 (en) | 2013-06-13 | 2019-03-19 | Zivo Bioscience, Inc. | Compounds and methods for affecting cytokines |
| US10842179B2 (en) | 2010-02-22 | 2020-11-24 | Zivo Bioscience, Inc. | Agents and mechanisms for treating hypercholesterolemia |
| US11806375B2 (en) | 2016-02-16 | 2023-11-07 | Zivo Bioscience, Inc. | Nutritional support for animals via administration of an algal derived supplement |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1190019A (en) * | 1998-03-05 | 1998-08-12 | 胥泽 | Ointment for trauma and fracture and its preparation |
| CN1416849A (en) * | 2001-11-05 | 2003-05-14 | 张高军 | Externally applied medicine for treating mastopathy and its prepn |
| CN1628745A (en) * | 2003-12-16 | 2005-06-22 | 董屹 | Antiinflammation pain relieving liquor |
| CN1907412A (en) * | 2006-08-07 | 2007-02-07 | 范振之 | Chinese medicinal capsule for treating breast phymatosis |
| CN1966045A (en) * | 2006-11-09 | 2007-05-23 | 李延山 | Chinese medicine for treating acute mastitis |
| CN1981797A (en) * | 2005-12-13 | 2007-06-20 | 潘明 | Medicinal liquor for treating mastadenitis |
-
2011
- 2011-06-21 CN CN2011101664167A patent/CN102225127B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1190019A (en) * | 1998-03-05 | 1998-08-12 | 胥泽 | Ointment for trauma and fracture and its preparation |
| CN1416849A (en) * | 2001-11-05 | 2003-05-14 | 张高军 | Externally applied medicine for treating mastopathy and its prepn |
| CN1628745A (en) * | 2003-12-16 | 2005-06-22 | 董屹 | Antiinflammation pain relieving liquor |
| CN1981797A (en) * | 2005-12-13 | 2007-06-20 | 潘明 | Medicinal liquor for treating mastadenitis |
| CN1907412A (en) * | 2006-08-07 | 2007-02-07 | 范振之 | Chinese medicinal capsule for treating breast phymatosis |
| CN1966045A (en) * | 2006-11-09 | 2007-05-23 | 李延山 | Chinese medicine for treating acute mastitis |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10166270B2 (en) | 2004-04-23 | 2019-01-01 | Zivo Bioscience, Inc. | Composition and method for affecting cytokines and NF-κB |
| US10842179B2 (en) | 2010-02-22 | 2020-11-24 | Zivo Bioscience, Inc. | Agents and mechanisms for treating hypercholesterolemia |
| US10232028B2 (en) | 2013-06-13 | 2019-03-19 | Zivo Bioscience, Inc. | Compounds and methods for affecting cytokines |
| US10765732B2 (en) | 2013-06-13 | 2020-09-08 | Zivo Bioscience, Inc. | Compounds and methods for affecting cytokines |
| CN104027699A (en) * | 2014-06-23 | 2014-09-10 | 烟台瑞智生物医药科技有限公司 | Traditional Chinese medicine (TCM) for treating distending pain of breasts during menstruation induced by symptom of deficiency of liver and kidney |
| EP3258948A4 (en) * | 2015-02-16 | 2018-09-12 | Zivo Bioscience, Inc. | Methods of modulating immune and inflammatory responses via administration of an algal biomass |
| US11065287B2 (en) | 2015-02-16 | 2021-07-20 | Zivo Bioscience, Inc. | Methods of modulating immune and inflammatory responses via administration of an algal biomass |
| US11806375B2 (en) | 2016-02-16 | 2023-11-07 | Zivo Bioscience, Inc. | Nutritional support for animals via administration of an algal derived supplement |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102225127B (en) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102225127B (en) | Traditional Chinese medicine composite for treating mastitis of dairy cattle | |
| CN110559363A (en) | Traditional Chinese medicine compound fermented oral liquid for preventing and treating African swine fever and preparation process thereof | |
| CN101744924B (en) | Multiple-effect Chinese herbal medicine compound of bacterial diseases of turbot | |
| CN101411782A (en) | Pharmaceutical composition for treating acute pharyngitis and preparation method thereof | |
| CN103263485B (en) | Traditional Chinese medicine composition for preventing and treating recessive mastitis of dairy cow and application thereof | |
| CN104367746A (en) | Compound traditional Chinese medicine perfusion agent used for treating endometritis of dairy cow and preparation method of compound traditional Chinese medicine perfusion agent | |
| CN101972391A (en) | Medicinal composition used for treating swine mastitis and preparation method thereof | |
| CN102058667B (en) | Chinese medical intramammary infusion for treating mastitis of dairy cows and preparation method thereof | |
| CN103169849A (en) | Pharmaceutical composition for treating sore carbuncle swollen poison, and preparation method and use thereof | |
| CN105213854A (en) | Agent raised by the Chinese medicine of a kind of prophylactic treatment chicken rabbit diarrhoea and yellow urine disease | |
| CN104840581B (en) | It is a kind of to be used to treat slow Chinese veterinary medicinal composition of sow prolonged lochia, heat and preparation method thereof | |
| CN103083396A (en) | Formula and preparation method of traditional Chinese medicine granule for prevention and treatment of cow subclinical mastitis | |
| CN102824440B (en) | Traditional Chinese medicine composition for treating dairy cow mastitis and preparation method thereof | |
| CN101401903B (en) | Chinese medicinal composition for treating endometritis of cow | |
| CN103893259A (en) | Novel traditional Chinese medicine composition for controlling recessive mastitis and preparation method thereof | |
| CN103961477B (en) | The endo-medicine and its preparation method of preventing and treating nursing period at initial stage acute mastitis | |
| CN109646546A (en) | It is a kind of for preventing and treating the Chinese medicine composition and preparation method thereof of livestock diarrhea | |
| CN104415100A (en) | Compound traditional Chinese medicine powder for treating cow mastitis | |
| CN114129654B (en) | Pharmaceutical composition and preparation for treating cow mastitis | |
| CN113876853B (en) | Medicine for preventing and treating cow mastitis disease and preparation method and application thereof | |
| CN103816265B (en) | A kind ofly be used for the treatment of medicine of having loose bowels and preparation method thereof | |
| CN101653567A (en) | Chinese veterinary medicament oral liquid for preventing and treating piglet yellow or white dysentery and preparation method thereof | |
| CN101972328A (en) | Chinese medicinal composition for treating sow milk-lacking symptom and preparation method thereof | |
| CN105726681A (en) | Injection for treating dairy cattle endometritis and preparing method of injection | |
| CN106266557A (en) | A kind of Chinese medicine preparation treating colpitis mycotica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BAODING JIZHONG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING JIUCAOTANG PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. Effective date: 20150603 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100085 HAIDIAN, BEIJING TO: 071500 BAODING, HEBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150603 Address after: 071500 industrial city, Gaoyang County, Hebei, Baoding Patentee after: Baoding Jizhong Pharmaceutical Co., Ltd. Address before: 100085, Beijing, Haidian District on the road No. 26, Zhongguancun venture building, room 1012 Patentee before: Beijing Jiucaotang Pharmaceutical Research Institute Co., Ltd. |